nach oben

Die Onkologie

Erschienen in:

01.09.2011 | Außer der Reihe

Psychoneuroimmunologie und Krebs

Neue Ergebnisse zu psychosozialen Einflüssen auf Tumorerkrankungen

verfasst von: Dr. J. Hefner, H. Csef

Erschienen in: Die Onkologie | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Aktuelle Arbeiten deuten auf einen Einfluss psychischer Faktoren auf den Krankheitsverlauf bei Krebs hin. Bei der Suche nach den zugrunde liegenden Mechanismen konzentrierte sich die psychoneuroimmunologische Forschung auf den Einfluss von psychischer Belastung bzw. von Stresshormonen auf die Wechselwirkungen von Immunsystem und Tumorzelle. Dabei wurden natürliche Killer (NK)-Zellen bisher am umfangreichsten untersucht. Doch die Ergebnisse sind inkonsistent, und so führte dies – in Anlehnung an die onkologische Forschung – zu einer Verschiebung des Fokus hin zu Untersuchungen des „tumor microenvironment“. Hier wurden in den letzten Jahren zu einzelnen Tumorentitäten neue Erkenntnisse gewonnen, die durch Gemeinsamkeiten der Pathophysiologie auch für die Onkologie bedeutsam sind. Weiterhin unklar bleibt dabei die Relevanz der Befunde für den Krankheitsverlauf bei Krebs.

Ader R, Cohen N (1975) Behaviorally conditioned immunosuppression. Psychosom Med 37:333–340PubMed

Akaho R et al (2003) Psychological factors and survival after bone marrow transplantation in patients with leukemia. Psychiatry Clin Neurosci 57:91–96PubMedCrossRef

Alesci S et al (2005) Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab 90:2522–2530PubMedCrossRef

Andersen BL et al (1998) Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst 90:30–36PubMedCrossRef

Andersen BL et al (2008) Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer 113:3450–3458PubMedCrossRef

Andrykowski MA (2005) Depression and survival after hematopoietic stem cell transplantation: where do we go from here? J Clin Oncol 23:5878–5880PubMedCrossRef

Andrykowski MA, Brady MJ, Henslee-Downey PJ (1994) Psychosocial factors predictive of survival after allogeneic bone marrow transplantation for leukemia. Psychosom Med 56:432–439PubMed

Badino GR et al (1996) Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res 33:255–260PubMedCrossRef

Barraclough J et al (1992) Life events and breast cancer prognosis. BMJ 304:1078–1081PubMedCrossRef

10.

Baxevanis CN et al (1993) Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 72:491–501PubMedCrossRef

11.

Ben-Eliyahu S, Page GG, Schleifer SJ (2007) Stress, NK cells, and cancer: still a promissory note. Brain Behav Immun 21:881–887PubMedCrossRef

12.

Benish M et al (2008) Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 15:2042–2052PubMedCrossRef

13.

Benjamin JE, Gill S, Negrin RS (2010) Biology and clinical effects of natural killer cells in allogeneic transplantation. Curr Opin Oncol 22:130–137PubMedCrossRef

14.

Bierhaus A et al (2003) A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 100:1920–1925PubMedCrossRef

15.

Blomberg BB et al (2009) Psychosocial adaptation and cellular immunity in breast cancer patients in the weeks after surgery: an exploratory study. J Psychosom Res 67:369–376PubMedCrossRef

16.

Blume J, Douglas SD, Evans DL (2011) Immune suppression and immune activation in depression. Brain Behav Immun 25:221–229PubMedCrossRef

17.

Boesen EH et al (2007) Survival after a psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 25:5698–5703PubMedCrossRef

18.

Broers S et al (1998) Are pretransplant psychological variables related to survival after bone marrow transplantation? A prospective study of 123 consecutive patients. J Psychosom Res 45:341–351PubMedCrossRef

19.

Buddeberg C, Buddeberg-Fischer B, Schnyder U (1997) Coping strategies and 10-year outcome in early breast cancer. J Psychosom Res 43:625–626PubMedCrossRef

20.

Burnet FM (1970) The concept of immunological surveillance. Prog Exp Tumor Res 13:1–27PubMed

21.

Butow PN, Coates AS, Dunn SM (2000) Psychosocial predictors of survival: metastatic breast cancer. Ann Oncol 11:469–474PubMedCrossRef

22.

Carbone E et al (2005) HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105:251–258PubMedCrossRef

23.

Carie AE, Sebti SM (2007) A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene 26:3777–3788PubMedCrossRef

24.

Chan AS et al (2007) Dopaminergic and adrenergic toxicities on SK-N-MC human neuroblastoma cells are mediated through G protein signaling and oxidative stress. Apoptosis 12:167–179PubMedCrossRef

25.

Chang G et al (2004) Predictors of 1-year survival assessed at the time of bone marrow transplantation. Psychosomatics 45:378–385PubMedCrossRef

26.

Chen ML, Chen MC, Yu CT (2010) Depressive symptoms during the first chemotherapy cycle predict mortality in patients with advanced non-small cell lung cancer. Support Care Cancer, doi 10.1007/s00520-010-1005-8

27.

Cohen S (2004) Social relationships and health. Am Psychol 59:676–684PubMedCrossRef

28.

Costanzo ES et al (2005) Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 104:305–313PubMedCrossRef

29.

Dantzer R et al (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56PubMedCrossRef

30.

De Brabander B, Gerits P (1999) Chronic and acute stress as predictors of relapse in primary breast cancer patients. Patient Educ Couns 37:265–272CrossRef

31.

Dean C, Surtees PG (1989) Do psychological factors predict survival in breast cancer? J Psychosom Res 33:561–569PubMedCrossRef

32.

Derogatis LR, Abeloff MD, Melisaratos N (1979) Psychological coping mechanisms and survival time in metastatic breast cancer. JAMA 242:1504–1508PubMedCrossRef

33.

Dhodapkar MV et al (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197:1667–1676PubMedCrossRef

34.

Disis ML, Lyerly HK (2005) Global role of the immune system in identifying cancer initiation and limiting disease progression. J Clin Oncol 23:8923–8925PubMedCrossRef

35.

Dong HP et al (2006) NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 125:451–458PubMed

36.

Drell TL et al (2003) Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80:63–70PubMedCrossRef

37.

Duan Z et al (2006) Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 12:5055–5063PubMedCrossRef

38.

Enserink JM et al (2004) The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin. J Biol Chem 279:44889–44896PubMedCrossRef

39.

Forsen A (1991) Psychosocial stress as a risk for breast cancer. Psychother Psychosom 55:176–185PubMedCrossRef

40.

Fredriksson JM et al (2000) Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta-adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2. J Biol Chem 275:13802–13811PubMedCrossRef

41.

Frick E et al (2005) Is perceived social support a predictor of survival for patients undergoing autologous peripheral blood stem cell transplantation? Psychooncology 14:759–770PubMedCrossRef

42.

Funch DP, Marshall J (1983) The role of stress, social support and age in survival from breast cancer. J Psychosom Res 27:77–83PubMedCrossRef

43.

Gilbar O (1996) The connection between the psychological condition of breast cancer patients and survival. A follow-up after eight years. Gen Hosp Psychiatry 18:266–270PubMedCrossRef

44.

Giraldi T et al (1997) Psychosocial factors and breast cancer: a 6-year Italian follow-up study. Psychother Psychosom 66:229–236PubMedCrossRef

45.

Glasner A et al (2010) Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 184:2449–2457PubMedCrossRef

46.

Goldberg JE, Schwertfeger KL (2010) Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 11:1133–1146PubMedCrossRef

47.

Goodwin PJ et al (2001) The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 345:1719–1726PubMedCrossRef

48.

Greer S et al (1990) Psychological response to breast cancer and 15-year outcome. Lancet 335:49–50PubMedCrossRef

49.

Herr I et al (2003) Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 63:3112–3120PubMed

50.

Hislop TG et al (1987) The prognostic significance of psychosocial factors in women with breast cancer. J Chronic Dis 40:729–735PubMedCrossRef

51.

Holden C (1978) Cancer and the mind: how are they connected? Science 200:1363–1369PubMedCrossRef

52.

Hong DS, Angelo LS, Kurzrock R (2007) Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 110:1911–1928PubMedCrossRef

53.

Hoodin F et al (2004) Psychosocial influences on 305 adults‘ survival after bone marrow transplantation; depression, smoking, and behavioral self-regulation. J Psychosom Res 57:145–154PubMedCrossRef

54.

Hoodin F et al (2006) Do negative or positive emotions differentially impact mortality after adult stem cell transplant? Bone Marrow Transplant 38:255–264PubMedCrossRef

55.

Jamison RN, Burish TG, Wallston KA (1987) Psychogenic factors in predicting survival of breast cancer patients. J Clin Oncol 5:768–772PubMed

56.

Janknecht R et al (1996) The ETS-related transcription factor ERM is a nuclear target of signaling cascades involving MAPK and PKA. Oncogene 13:1745–1754PubMed

57.

Jehn CF et al (2006) Biomarkers of depression in cancer patients. Cancer 107:2723–2729PubMedCrossRef

58.

Jenkins PL et al (1994) A prospective study of psychosocial morbidity in adult bone marrow transplant recipients. Psychosomatics 35:361–367PubMed

59.

Jensen MR (1987) Psychobiological factors predicting the course of breast cancer. J Pers 55:317–342PubMedCrossRef

60.

Kamat AA et al (2006) The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 12:1707–1714PubMedCrossRef

61.

Konjevic G, Spuzic I (1993) Stage dependence of NK cell activity and its modulation by interleukin 2 in patients with breast cancer. Neoplasma 40:81–85PubMed

62.

Kovaru H et al (2009) Cell signalling in CNS and immune system in depression and during antidepressant treatment: focus on glial and natural killer cells. Neuro Endocrinol Lett 30:421–428PubMed

63.

Kroenke CH et al (2006) Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol 24:1105–1111PubMedCrossRef

64.

Lahdenpohja N, Henttinen T, Hurme M (1996) Activation of the protein kinase A increases the DNA-binding and transcriptional activity of c-Rel in T cells. Scand J Immunol 43:640–645PubMedCrossRef

65.

Landen CN Jr et al (2007) Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res 67:10389–10396PubMedCrossRef

66.

Lang K et al (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112:231–238PubMedCrossRef

67.

Lanquillon S et al (2000) Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22:370–379PubMedCrossRef

68.

Lee SJ et al (2003) Optimistic expectations and survival after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 9:389–396PubMedCrossRef

69.

Levy S et al (1987) Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. J Clin Oncol 5:348–353PubMed

70.

Levy SM et al (1991) Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav Med 17:67–75PubMedCrossRef

71.

Levy SM et al (1985) Prognostic risk assessment in primary breast cancer by behavioral and immunological parameters. Health Psychol 4:99–113PubMedCrossRef

72.

Levy SM et al (1988) Survival hazards analysis in first recurrent breast cancer patients: seven-year follow-up. Psychosom Med 50:520–528PubMed

73.

Loberiza FR Jr et al (2002) Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol 20:2118–2126PubMedCrossRef

74.

Lutgendorf SK et al (2003) Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 9:4514–4521PubMed

75.

Lutgendorf SK et al (2009) Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun 23:176–183PubMedCrossRef

76.

Lutgendorf SK et al (2002) Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer 95:808–815PubMedCrossRef

77.

Lutgendorf SK et al (2008) Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res 14:6839–6846PubMedCrossRef

78.

Lutgendorf SK et al (2005) Distress and expression of natural killer receptors on lymphocytes. Brain Behav Immun 19:185–194PubMedCrossRef

79.

Lutgendorf SK et al (2005) Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol 23:7105–7113PubMedCrossRef

80.

Lutgendorf SK et al (2008) Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 26:4820–4827PubMedCrossRef

81.

Luttrell LM et al (1999) Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283:655–661PubMedCrossRef

82.

Machein MR et al (1999) Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol 25:104–112PubMedCrossRef

83.

Maes M et al (1993) Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 49:11–27PubMedCrossRef

84.

Marchetti B et al (1991) A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of beta-adrenergic receptors and correlation with tumor growth. J Steroid Biochem Mol Biol 38:307–320PubMedCrossRef

85.

Masur K et al (2001) Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61:2866–2869PubMed

86.

Maunsell E, Brisson J, Deschenes L (1995) Social support and survival among women with breast cancer. Cancer 76:631–637PubMedCrossRef

87.

Maunsell E et al (2001) Stressful life events and survival after breast cancer. Psychosom Med 63:306–315PubMed

88.

McCoy JL, Rucker R, Petros JA (2000) Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. Breast Cancer Res Treat 60:227–234PubMedCrossRef

89.

Melief CJ, Kast WM (1991) T-cell immunotherapy of cancer. Res Immunol 142:425–429PubMedCrossRef

90.

Miller GE, Rohleder N, Cole SW (2009) Chronic interpersonal stress predicts activation of pro- and anti-inflammatory signaling pathways 6 months later. Psychosom Med 71:57–62PubMedCrossRef

91.

Molassiotis A, van den Akker OB, Boughton BJ (1997) Perceived social support, family environment and psychosocial recovery in bone marrow transplant long-term survivors. Soc Sci Med 44:317–325PubMedCrossRef

92.

Montminy M (1997) Transcriptional regulation by cyclic AMP. Annu Rev Biochem 66:807–822PubMedCrossRef

93.

Moradi MM et al (1993) Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 72:2433–2440PubMedCrossRef

94.

Moran TJ et al (2000) The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res 60:867–872PubMed

95.

Nilsson MB et al (2007) Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem 282:29919–29926PubMedCrossRef

96.

Palm D et al (2006) The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 118:2744–2749PubMedCrossRef

97.

Pang D et al (2006) Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther 5:933–940PubMedCrossRef

98.

Penson RT et al (2000) Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10:33–41PubMedCrossRef

99.

Pifl C et al (2001) Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter. FASEB J 15:1607–1609PubMed

100.

Plante M et al (1994) Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73:1882–1888PubMedCrossRef

101.

Prieto JM et al (2005) Role of depression as a predictor of mortality among cancer patients after stem-cell transplantation. J Clin Oncol 23:6063–6071PubMedCrossRef

102.

Rangarajan S et al (2003) Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic receptor. J Cell Biol 160:487–493PubMedCrossRef

103.

Rath KS et al (2010) Expression of soluble interleukin-6 receptor in malignant ovarian tissue. Am J Obstet Gynecol 203:230, e1–e8PubMedCrossRef

104.

Reynolds P et al (1994) The relationship between social ties and survival among black and white breast cancer patients. National Cancer Institute Black/White Cancer Survival Study Group. Cancer Epidemiol Biomarkers Prev 3:253–259PubMed

105.

Reynolds P et al (2000) Use of coping strategies and breast cancer survival: results from the Black/White Cancer Survival Study. Am J Epidemiol 152:940–949PubMedCrossRef

106.

Richlin VA et al (2004) Stress-induced enhancement of NF-kappaB DNA-binding in the peripheral blood leukocyte pool: effects of lymphocyte redistribution. Brain Behav Immun 18:231–237PubMedCrossRef

107.

Ross L et al (2009) No effect on survival of home psychosocial intervention in a randomized study of Danish colorectal cancer patients. Psychooncology 18:875–885PubMedCrossRef

108.

Sastry KS et al (2007) Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem 282:14094–14100PubMedCrossRef

109.

Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 115:5349–5361PubMedCrossRef

110.

Scambia G et al (1995) Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71:354–356PubMedCrossRef

111.

Scarparo AC, Visconti MA, Castrucci AM (2006) Signalling pathways evoked by alpha1-adrenoceptors in human melanoma cells. Cell Biochem Funct 24:119–129PubMedCrossRef

112.

Schulz KH, Gold S (2006) Psychische Belastungen, Immunfunktionen und Krankheitsentwicklungen. Die psychoneuroimmunologische Perspektive. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 49:759–772PubMedCrossRef

113.

Sephton SE et al (2009) Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav Immun 23:1148–1155PubMedCrossRef

114.

Sephton SE et al (2000) Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 92:994–1000PubMedCrossRef

115.

Shahzad MM et al (2010) Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 285:35462–35470PubMedCrossRef

116.

Shirakawa F, Mizel SB (1989) In vitro activation and nuclear translocation of NF-kappa B catalyzed by cyclic AMP-dependent protein kinase and protein kinase C. Mol Cell Biol 9:2424–2430PubMed

117.

Simon WE et al (1984) In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin. J Natl Cancer Inst 73:313–321PubMed

118.

Sood AK et al (2010) Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 120:1515–1523PubMedCrossRef

119.

Sood AK et al (2006) Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12:369–375PubMedCrossRef

120.

Spiegel D, Giese-Davis J (2003) Depression and cancer: mechanisms and disease progression. Biol Psychiatry 54:269–282PubMedCrossRef

121.

Su F et al (2005) Psychological stress induces chemoresistance in breast cancer by upregulating mdr1. Biochem Biophys Res Commun 329:888–897PubMedCrossRef

122.

Temel JS et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742PubMedCrossRef

123.

Thaker PH et al (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939–944PubMedCrossRef

124.

Thaker PH, Lutgendorf SK, Sood AK (2007) The neuroendocrine impact of chronic stress on cancer. Cell Cycle 6:430–433PubMedCrossRef

125.

Thaker PH, Sood AK (2008) Neuroendocrine influences on cancer biology. Semin Cancer Biol 18:164–170PubMedCrossRef

126.

Thornton LM et al (2007) Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav Immun 21:185–194PubMedCrossRef

127.

Trikas P et al (2002) Low psychopathology scores in the prognosis of breast cancer. A preliminary report. Psychother Psychosom 71:162–167PubMedCrossRef

128.

Tross S et al (1996) Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. J Natl Cancer Inst 88:661–667PubMedCrossRef

129.

Tschuschke V et al (2001) Associations between coping and survival time of adult leukemia patients receiving allogeneic bone marrow transplantation: results of a prospective study. J Psychosom Res 50:277–285PubMedCrossRef

130.

Tsigos C, Chrousos GP (2002) Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 53:865–871PubMedCrossRef

131.

Vandewalle B, Revillion F, Lefebvre J (1990) Functional beta-adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 116:303–306PubMedCrossRef

132.

Vossler MR et al (1997) cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 89:73–82PubMedCrossRef

133.

Watson M et al (2005) Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort. Eur J Cancer 41:1710–1714PubMedCrossRef

134.

Waxler-Morrison N et al (1991) Effects of social relationships on survival for women with breast cancer: a prospective study. Soc Sci Med 33:177–183PubMedCrossRef

135.

Webster JI, Tonelli L, Sternberg EM (2002) Neuroendocrine regulation of immunity. Annu Rev Immunol 20:125–163PubMedCrossRef

136.

Wei LH et al (2003) Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22:1517–1527PubMedCrossRef

137.

Weihs KL et al (2000) Negative affectivity, restriction of emotions, and site of metastases predict mortality in recurrent breast cancer. J Psychosom Res 49:59–68PubMedCrossRef

138.

Whiteside TL, Herberman RB (1989) The role of natural killer cells in human disease. Clin Immunol Immunopathol 53:1–23PubMedCrossRef

139.

Wu J, Janknecht R (2002) Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A. J Biol Chem 277:42669–42679PubMedCrossRef

140.

Wu W et al (2004) Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 64:1757–1764PubMedCrossRef

141.

Yamasaki S et al (1993) Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy. Breast Cancer Res Treat 26:55–65PubMedCrossRef

142.

Yang EV et al (2006) Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 66:10357–10364PubMedCrossRef

143.

Zhao XY et al (2000) Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6:703–706PubMedCrossRef

144.

Zhong H, Voll RE, Ghosh S (1998) Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1:661–671PubMedCrossRef

145.

Zorrilla EP et al (2001) The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 15:199–226PubMedCrossRef

Titel: Psychoneuroimmunologie und Krebs
Neue Ergebnisse zu psychosozialen Einflüssen auf Tumorerkrankungen
verfasst von: Dr. J. Hefner
H. Csef
Publikationsdatum: 01.09.2011
Verlag: Springer-Verlag
Erschienen in: Die Onkologie / Ausgabe 9/2011
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI: https://doi.org/10.1007/s00761-011-2077-x

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Psychoneuroimmunologie und Krebs

Neue Ergebnisse zu psychosozialen Einflüssen auf Tumorerkrankungen

Zusammenfassung

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2011

Therapie von ZNS-Lymphomen

Das Bessere ist des Guten Feind

Therapie des Mantelzelllymphoms

Tumorbedingte Fatigue

3. Europäisches Konsensusmeeting zum Hodentumor

Die Rolle der Strahlentherapie bei seltenen extranodalen Non-Hodgkin-Lymphomen

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie